Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months

ABSTRACT: SARS-CoV-2 vaccines have shown very high effectiveness in real-world scenarios. However, there is compelling evidence for a fast-paced waning of immunity. The increasing number of new variants that could alter the severity, transmissibility, and potential to evade the immune response raise...

Full description

Autores:
Lopera Restrepo, Tulio José
Medina Chvatal, Mateo
Flórez Álvarez, Lizdany
Zapata Cardona, María Isabel
Taborda Vanegas, Natalia Andrea
Rugeles López, María Teresa
Hernández López, Juan Carlos
Tipo de recurso:
Article of investigation
Fecha de publicación:
2022
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/35566
Acceso en línea:
https://hdl.handle.net/10495/35566
Palabra clave:
SARS-CoV-2
Vacunas contra la COVID-19
COVID-19 Vaccines
Anticuerpos Neutralizantes
Antibodies, Neutralizing
Inmunogenicidad Vacunal
Immunogenicity, Vaccine
Vacuna BNT162
BNT162 Vaccine
Estudios Prospectivos
Prospective Studies
Variant
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/